{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:50:25Z","timestamp":1793155825935,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005339","name":"American Academy of Neurology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jocn-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jocn.2025.111211","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T04:57:12Z","timestamp":1743656232000},"page":"111211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Safety and efficacy of anti-IL-17A use in multiple sclerosis and comorbid rheumatological disease: A multi-center exploratory study"],"prefix":"10.1016","volume":"136","author":[{"given":"Evan","family":"Madill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Galetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwasinmisola","family":"Opeyemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle Kei","family":"Pua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Gandelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanuja","family":"Chitnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamik","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jocn.2025.111211_b0005","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/JID.2015.350","article-title":"Risk of multiple sclerosis in patients with psoriasis: a Danish nationwide cohort study","volume":"136","author":"Egeberg","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jocn.2025.111211_b0010","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/1352458514564490","article-title":"A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.jocn.2025.111211_b0015","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/511051","article-title":"A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes","volume":"80","author":"Cargill","year":"2007","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.jocn.2025.111211_b0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/gene.2008.16","article-title":"IL23R: a susceptibility locus for celiac disease and multiple sclerosis?","volume":"9","author":"Nunez","year":"2008","journal-title":"Genes Immun"},{"issue":"4","key":"10.1016\/j.jocn.2025.111211_b0025","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028522","article-title":"17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications","volume":"10","author":"Monin","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.jocn.2025.111211_b0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-065X.2008.00699.x","article-title":"The roles of IL-17A in inflammatory immune responses and host defense against pathogens","volume":"226","author":"Iwakura","year":"2008","journal-title":"Immunol Rev"},{"issue":"4","key":"10.1016\/j.jocn.2025.111211_b0035","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.immuni.2008.03.004","article-title":"The biological functions of T helper 17 cell effector cytokines in inflammation","volume":"28","author":"Ouyang","year":"2008","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.jocn.2025.111211_b0040","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI5703","article-title":"IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis","volume":"103","author":"Kotake","year":"1999","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.jocn.2025.111211_b0045","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"van der Fits","year":"2009","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.jocn.2025.111211_b0050","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41423-021-00644-5","article-title":"Local and systemic effects of IL-17 in joint inflammation: a historical perspective from discovery to targeting","volume":"18","author":"Miossec","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"10.1016\/j.jocn.2025.111211_b0055","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm0502-500","article-title":"Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis","volume":"8","author":"Lock","year":"2002","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jocn.2025.111211_b0060","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2353\/ajpath.2008.070690","article-title":"Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis","volume":"172","author":"Tzartos","year":"2008","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.jocn.2025.111211_b0065","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2567.2008.02837.x","article-title":"T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis","volume":"125","author":"Hedegaard","year":"2008","journal-title":"Immunology"},{"issue":"22","key":"10.1016\/j.jocn.2025.111211_b0070","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.4155\/bio-2016-0207","article-title":"Characterization of IL-17AA and IL-17FF in rheumatoid arthritis and multiple sclerosis","volume":"8","author":"Schofield","year":"2016","journal-title":"Bioanalysis"},{"issue":"7","key":"10.1016\/j.jocn.2025.111211_b0075","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00415-016-8128-x","article-title":"Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study","volume":"263","author":"Havrdova","year":"2016","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.jocn.2025.111211_b0080","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1111\/jdv.16035","article-title":"Secukinumab for patients with plaque psoriasis affected by multiple sclerosis: a mini-review with a representative case report","volume":"34","author":"Venturini","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.jocn.2025.111211_b0085","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1111\/ijd.14902","article-title":"Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis?","volume":"59","author":"Megna","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jocn.2025.111211_b0090","article-title":"Successful treatment of highly active multiple sclerosis and psoriasis exacerbation with natalizumab and secukinumab combination. A case report and literature review","volume":"2","author":"Kougkas","year":"2022","journal-title":"Neuroimmunol Rep"},{"key":"10.1016\/j.jocn.2025.111211_b0095","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.msard.2019.03.009","article-title":"A case of concomitant psoriasis and multiple sclerosis: secukinumab and rituximab exert dichotomous effects in two autoimmune conditions","volume":"31","author":"Diebold","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.jocn.2025.111211_b0100","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/1346-8138.17143","article-title":"Risk of multiple sclerosis in patients with psoriasis receiving anti-IL-17 agents: a case-based review","volume":"51","author":"Tsiogkas","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.jocn.2025.111211_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101884","article-title":"Clinical instrument to retrospectively capture levels of EDSS","volume":"39","author":"Ciotti","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.jocn.2025.111211_b0110","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200211","article-title":"Multiple sclerosis, rituximab, hypogammaglobulinemia, and risk of infections","volume":"11","author":"Langer-Gould","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"10.1016\/j.jocn.2025.111211_b0115","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.cgh.2023.09.010","article-title":"Vedolizumab, adalimumab, and methotrexate combination therapy in crohn's disease (EXPLORER)","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jocn.2025.111211_b0120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2018.12.003","article-title":"Safety of combination therapy with two bDMARDs in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"49","author":"Boleto","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.jocn.2025.111211_b0125","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ibd.20014","article-title":"Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab","volume":"13","author":"Sands","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"10.1016\/j.jocn.2025.111211_b0130","first-page":"406","article-title":"Efficacy and safety of dual biologic therapy in patients with inflammatory bowel disease: a review of the literature","volume":"17","author":"Gold","year":"2021","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"7","key":"10.1016\/j.jocn.2025.111211_b0135","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","article-title":"Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial","volume":"22","author":"Corboy","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2025.111211_b0140","article-title":"Discontinuation of first-line disease-modifying therapy in patients with stable multiple sclerosis: the DOT-MS randomized clinical trial","author":"Coerver","year":"2024","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.jocn.2025.111211_b0145","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13943","article-title":"Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis","volume":"33","author":"Di Tullio","year":"2020","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.jocn.2025.111211_b0150","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40265-017-0854-6","article-title":"Dimethyl fumarate: a review in moderate to severe plaque psoriasis","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825001833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825001833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T11:15:31Z","timestamp":1747134931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586825001833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":30,"alternative-id":["S0967586825001833"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111211","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of anti-IL-17A use in multiple sclerosis and comorbid rheumatological disease: A multi-center exploratory study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111211"}}